Isabela Panzeri Carlotti Buzatto
YOU?
Author Swipe
View article: PersonalizedUS: Interpretable Breast Cancer Risk Assessment with Local Coverage Uncertainty Quantification
PersonalizedUS: Interpretable Breast Cancer Risk Assessment with Local Coverage Uncertainty Quantification Open
Correctly assessing the malignancy of breast lesions identified during ultrasound examinations is crucial for effective clinical decision-making. However, the current "gold standard" relies on manual BI-RADS scoring by clinicians, often le…
View article: Uterine carcinosarcoma with microsatellite instability - does immunotherapy modify the therapeutic scenario? A case report and literature review
Uterine carcinosarcoma with microsatellite instability - does immunotherapy modify the therapeutic scenario? A case report and literature review Open
Carcinosarcomas were reclassified by World Health Organization as high-grade uterine carcinomas in 2014. Due to its rare histology, comprising only 5% of uterine carcinomas, there is a small representation of this tumor in studies that eva…
View article: Machine learning can reliably predict malignancy of BI-RADS 4a and 4b breast lesions based on clinical and ultrasonographic features
Machine learning can reliably predict malignancy of BI-RADS 4a and 4b breast lesions based on clinical and ultrasonographic features Open
Objective: The objectives of this study were to establish the most reliable machine learning model to predict malignancy in BI-RADS 4a and 4b breast lesions and optimize the negative predictive value to minimize unnecessary biopsies. Metho…
View article: Axillary ultrasound and fine-needle aspiration cytology to predict clinically relevant nodal burden in breast cancer patients
Axillary ultrasound and fine-needle aspiration cytology to predict clinically relevant nodal burden in breast cancer patients Open
View article: Use of Bivariate Lifetime Distributions Assuming Continuous or Discrete Data Applied to Patients with Breast Cancer
Use of Bivariate Lifetime Distributions Assuming Continuous or Discrete Data Applied to Patients with Breast Cancer Open
Breast cancer is the second most common type of cancer in the world (World Cancer Report, 2014 a, b). The evolution of breast cancer treatment usually allows a longer life of patients as well in many cases a relapse of the disease. Usually…
View article: Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors Open
The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 t…
View article: Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors Open
The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 t…